Asymmetric dimethylarginine and critical illness

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 17, Issue 1, 2014, Pages 90-97

  Brinkmann, Saskia J H ^a   De Boer, Myrte C ^a   Buijs, Nikki ^a   Van Leeuwen, Paul A M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Asymmetric dimethylarginine; Critical illness; Humans; ICU

Indexed keywords

N(G),N(G) DIMETHYLARGININE;

CRITICAL ILLNESS; CRITICALLY ILL PATIENT; HUMAN; INTENSIVE CARE; KIDNEY CLEARANCE; LIVER CLEARANCE; METABOLISM; MORBIDITY; MORTALITY; PROTEIN METABOLISM; PROTEIN METHYLATION; REVIEW; RISK FACTOR; SYNTHESIS;

AMIDOHYDROLASES; ARGININE; CRITICAL ILLNESS; ENZYME INHIBITORS; HEART FAILURE; HUMANS; INTENSIVE CARE UNITS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RISK FACTORS;

EID: 84891001220     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0000000000000020     Document Type: Review

References (45)

1. Leiper J, Nandi M. The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis. Nat Rev Drug Discov 2011; 10: 277-291.
2. Cha B, Jho EH. Protein arginine methyltransferases (PRMTs) as therapeutic targets. Expert Opin Ther Targets 2012; 16: 651-664.
3. Surdacki A. L-Arginine analogs: inactive markers or active agents in atherogenesis? Cardiovasc Hematol Agents Med Chem 2008; 6: 302-311.
4. Anderssohn M, Rosenberg M, Schwedhelm E, et al. The L-arginine- asymmetric dimethylarginine ratio is an independent predictor of mortality in dilated cardiomyopathy. J Card Fail 2012; 18: 904-911.
5. Seljeflot I, Nilsson BB, Westheim AS, et al. The L-arginine-asymmetric dimethylarginine ratio is strongly related to the severity of chronic heart failure. No effects of exercise training. J Card Fail 2011; 17: 135-142.
6. Richir MC, van Lambalgen AA, Teerlink T, et al. Low arginine/ asymmetric dimethylarginine ratio deteriorates systemic hemodynamics and organ blood flow in a rat model. Crit Care Med 2009; 37: 2010-2017.
7. Bode-Boger SM, Scalera F, Ignarro LJ. The L-arginine paradox: importance of the L-arginine/asymmetrical dimethylarginine ratio. Pharmacol Ther 2007; 114: 295-306. (Pubitemid 46843253)
8. Visser M, Paulus WJ, Vermeulen MA, et al. The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature. Eur J Heart Fail 2010; 12: 1274-1281.
9. Landim MB, Casella FA, Chagas AC. Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis. Clinics (Sao Paulo) 2009; 64: 471-478.
10. Forstermann U. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch 2010; 459: 923-939.
11. Davids M, Teerlink T. Plasma concentrations of arginine and asymmetric dimethylarginine do not reflect their intracellular concentrations in peripheral blood mononuclear cells. Metabolism 2013; 62: 1455-1461.
12. Blackwell S. The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine. Ann Clin Biochem 2010; 47: 17-28.
13. Davids M, Richir MC, Visser M, et al. Role of dimethylarginine dimethylaminohydrolase activity in regulation of tissue and plasma concentrations of asymmetric dimethylarginine in an animal model of prolonged critical illness. Metabolism 2012; 61: 482-490.
14. Betz B, Moller-Ehrlich K, Kress T, et al. Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency. Transl Res 2013; 162: 67-76.
15. Pope AJ, Karuppiah K, Cardounel AJ. Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide production. Pharmacol Res 2009; 60: 461-465.
16. Raptis V, Kapoulas S, Grekas D. Role of asymmetrical dimethylarginine in the progression of renal disease. Nephrology (Carlton) 2013; 18: 11-21.
17. Aldamiz-Echevarria L, Andrade F. Asymmetric dimethylarginine, endothelial dysfunction and renal disease. Int J Mol Sci 2012; 13: 11288-11311.
18. Oner-Iyidogan Y, Oner P, Kocak H, et al. Dimethylarginines and inflammation markers in patients with chronic kidney disease undergoing dialysis. Clin Exp Med 2009; 9: 235-241.
19. Iapichino G, Umbrello M, Albicini M, et al. Time course of endogenous nitric oxide inhibitors in severe sepsis in humans. Minerva Anestesiol 2010; 76: 325-333.
20. Abedini S, Meinitzer A, Holme I, et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. Kidney Int 2010; 77: 44-50.
21. Zhang DL, Liu J, Liu S, et al. The differences of asymmetric dimethylarginine removal by different dialysis treatments. Ren Fail 2010; 32: 935-940.
22. Kielstein JT, Zoccali C. Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens 2008; 17: 609-615.
23. Nijveldt RJ, Teerlink T, van Leeuwen PA. The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis. Clin Nutr 2003; 22: 99-104. (Pubitemid 36193187)
24. Boger RH. Live and let die: asymmetric dimethylarginine and septic shock. Crit Care 2006; 10:169.
25. Nijveldt RJ, Teerlink T, Siroen MP, et al. Elevation of asymmetric dimethylarginine (ADMA) in patients developing hepatic failure after major hepatectomy. JPEN J Parenter Enteral Nutr 2004; 28: 382-387. (Pubitemid 39463821)
26. Kajimoto H, Kai H, Aoki H, et al. Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine. Kidney Int 2012; 81: 762-768.
27. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345: 1359-1367.
28. Ellger B, Richir MC, van Leeuwen PA, et al. Glycemic control modulates arginine and asymmetrical-dimethylarginine levels during critical illness by preserving dimethylarginine-dimethylaminohydrolase activity. Endocrinology 2008; 149: 3148-3157. (Pubitemid 351724509)
29. Siroen MP, van Leeuwen PA, Nijveldt RJ, et al. Modulation of asymmetric dimethylarginine in critically ill patients receiving intensive insulin treatment: a possible explanation of reduced morbidity and mortality? Crit Care Med 2005; 33: 504-510. (Pubitemid 40365549)
30. Nijveldt RJ, Teerlink T, Van Der HB, et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 2003; 22: 23-30. (Pubitemid 36193177)
31. Preiser JC, Luiking Y, Deutz N. Arginine and sepsis: a question of the right balance? Crit Care Med 2011; 39: 1569-1570.
32. Siegerink B, Maas R, Vossen CY, et al. Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA followup study. Clin Res Cardiol 2013; 102: 193-202.
33. Trzeciak S, Cinel I, Phillip DR, et al. Resuscitating the microcirculation in sepsis: the central role of nitric oxide, emerging concepts for novel therapies, and challenges for clinical trials. Acad Emerg Med 2008; 15: 399-413.
34. Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev 2010; 6: 82-90.
35. Cauwels A, Brouckaert P. Nitrite regulation of shock. Cardiovasc Res 2011; 89: 553-559.
36. Lopez A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebocontrolled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004; 32: 21-30. (Pubitemid 38125559)
37. Zairis MN, Patsourakos NG, Tsiaousis GZ, et al. Plasma asymmetric dimethylarginine and mortality in patients with acute decompensation of chronic heart failure. Heart 2012; 98: 860-864.
38. Davis JS, Darcy CJ, Yeo TW, et al. Asymmetric dimethylarginine, endothelial nitric oxide bioavailability and mortality in sepsis. PLoS One 2011; 6:e17260.
39. Gough MS, Morgan MA, Mack CM, et al. The ratio of arginine to dimethylarginines is reduced and predicts outcomes in patients with severe sepsis. Crit Care Med 2011; 39: 1351-1358.
40. Visser M, Vermeulen MA, RichirMC, et al. Imbalance of arginine and asymmetric dimethylarginine is associated with markers of circulatory failure, organ failure and mortality in shock patients. Br J Nutr 2012; 107: 1458-1465. This study points out the importance of nitric oxide for cardiac function and elucidates the role of the arginine :ADMA ratio in the pathophysiological mechanisms in shock.
41. Brenner T, Fleming TH, Rosenhagen C, et al. L-Arginine and asymmetric dimethylarginine are early predictors for survival in septic patients with acute liver failure. Mediators Inflamm 2012. doi: 10.1155/2012/210454. [Epub ahead of print]
42. Weiss SL, Haymond S, Ralay RH, et al. Evaluation of asymmetric dimethylarginine, arginine, and carnitine metabolism in pediatric sepsis. Pediatr Crit Care Med 2012; 13:e210-e218.
43. Hassinger AB, Wainwright MS, Lane JC, et al. Elevated preoperative serum asymmetrical dimethylarginine (ADMA) is associated with poor outcomes after pediatric cardiac surgery. Intensive Care Med 2012; 38: 1697-1704.
44. Koch A, Weiskirchen R, Kunze J, et al. Elevated asymmetric dimethylarginine levels predict short- and long-term mortality risk in critically ill patients. J Crit Care 2013; 28: 947-953.
45. Bouras G, Deftereos S, Tousoulis D, et al. Asymmetric dimethylarginine (ADMA): a promising biomarker for cardiovascular disease? Curr Top Med Chem 2013; 13: 180-200.